Скачать или смотреть KIM-1 in Metastatic Kidney cancer by Marc Machaalani ( ASCO 2025 )

Dr. Marc Machaalani | Groundbreaking Insights on KIM-1 as a Prognostic Biomarker in Renal Cell Carcinoma | ASCO 2025

Discover the latest breakthrough in kidney cancer research as Dr. Marc Machaalani unveils the critical role of circulating Kidney Injury Molecule-1 (KIM-1) in predicting outcomes for renal cell carcinoma (RCC). This integrative analysis from the JAVELIN Renal 101 trial links KIM-1 plasma levels with tumor burden, genetic mutations, and transcriptomic profiles, revealing its strong association with poor prognosis and aggressive tumor biology.

🔬 Learn how elevated KIM-1 correlates with BAP1 loss-of-function mutations, interferon gamma response, and proliferative gene signatures—independent of treatment type.

📈 Understand why KIM-1 could become a game-changing biomarker for RCC patient stratification and therapy planning.

👉 For oncologists, researchers, and anyone passionate about cutting-edge cancer science, this video delivers key insights you won’t want to miss.

📩 Don’t forget to subscribe and hit the notification bell for the latest updates from ASCO 2025!

#RenalCellCarcinoma #KIM1 #CancerBiomarkers #ASCO2025 #OncologyResearch #KidneyCancer #PrecisionMedicine